Our editorial standards

With the label. We type the brand's Supplement Facts first: 2 capsules per serving, five ingredients, every amount printed (SynoCell, product page).

When a detail is missing, such as other ingredients, allergens or warnings, we write "not published; read your bottle." We never fill a gap with a guess. See the full label.

Only when the ingredient, form and amount line up. The FTC asks for a comparable dose and formulation, and says lab work alone is not enough (FTC, Health Products Compliance Guidance).

• Close: ASU 310 mg versus 300 mg in trials (Cameron and Chrubasik, 2014); hyaluronic acid 180 mg versus 200 mg (Tashiro et al., 2012).
• Rough: Boswellia trials used other extracts at 100 or 250 mg (Sengupta et al., 2008) (Yu et al., 2020).
• None: quercetin has animal and lab data only (MSKCC, Quercetin). Piperine interaction studies used 15-20 mg (Horn and Hansten, 2017), so for 5 mg we say "ask your pharmacist."

Each review must match a real order, and the buyer must agree to publish it. We never pay for reviews. The FTC banned fake and bought reviews on August 14, 2024 (FTC, Final rule on fake reviews, 2024). Details are on the reviews page.

Email [email protected] with the page and the error. We correct it and change the update date. Prices were last checked October 11, 2026.

Sources behind these standards

1. Oral herbal therapies for treating osteoarthritis. Cameron M, Chrubasik S. Cochrane Database of Systematic Reviews, 2014.Cochrane review: in four trials (651 people) ASU 300 mg/day reduced pain by about 8.5 points on a 0-100 scale versus placebo, a small benefit of questionable clinical importance (moderate-quality evidence), with no significant effect on joint space width. For Boswellia, an enriched extract (5-Loxin 100 mg) reduced pain by about 17 points over 90 days and Aflapin 100 mg by about 16 points (moderate-quality evidence); no serious adverse events were linked to any herbal product, but safety data were limited.
2. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Maheu E, Cadet C, Marty M, et al. Annals of the Rheumatic Diseases, 2014.In 399 people with hip OA given ASU 300 mg/day or placebo for 3 years, average joint space loss did not differ (-0.638 mm vs -0.672 mm), although fewer patients were classed as progressors (40% vs 50%). There were no differences in pain, function or painkiller/NSAID use, and the authors say clinical relevance is unclear.
3. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. Yu GP, Xiang W, Zhang TQ, Zeng LT, Yang KL, Li J. BMC Complementary Medicine and Therapies, 2020.Pooling 7 randomized controlled trials with 545 patients, Boswellia or its extracts reduced pain (VAS and WOMAC pain) and stiffness and improved function compared with placebo or conventional medicine. The authors suggest treatment for at least 4 weeks; the trials were small and used different extracts.
4. Oral Administration of Polymer Hyaluronic Acid Alleviates Symptoms of Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Study over a 12-Month Period. Tashiro T, Seino S, Sato T, Matsuoka R, Masuda Y, Fukui N. TheScientificWorldJournal, 2012.60 adults with knee OA took 200 mg/day of oral HA or placebo for 12 months alongside daily quadriceps exercise; both groups improved, and HA was significantly better than placebo only in people aged 70 or younger. The authors conclude oral HA may improve symptoms in that younger subgroup.
5. Quercetin. Memorial Sloan Kettering Cancer Center, About Herbs, 2026.For osteoarthritis MSKCC cites only preclinical (animal and lab) data, not human trials. It warns quercetin may increase side effects of drugs metabolized by CYP3A4 or CYP2C19, may interact with losartan, and reports a case of raised INR in a man on warfarin.
6. Piperine Drug Interactions. Horn JR, Hansten PD. Pharmacy Times, 2017.In small human studies, piperine at about 15-20 mg/day raised blood levels of carbamazepine (AUC up 48%), diclofenac and fexofenadine (AUC up 68%), prolonged midazolam sedation, and modestly increased phenytoin, with preliminary evidence for propranolol and theophylline. Proposed mechanisms are inhibition of CYP3A4, CYP2C9 and P-glycoprotein.
7. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Kolasinski SL, Neogi T, Hochberg MC, et al. Arthritis and Rheumatology, 2020.Strongly recommended: exercise; weight loss for overweight knee/hip OA (at least 5% of body weight); tai chi and a cane for knee/hip OA; topical NSAIDs for knee OA; oral NSAIDs. Glucosamine is strongly recommended against for knee, hip and hand OA, chondroitin is strongly recommended against for knee/hip OA, and intra-articular hyaluronic acid is conditionally recommended against for knee OA (strongly against for hip); ASU, Boswellia and curcumin are not addressed.
8. 2026 Update of the American College of Rheumatology Recommendations for the Management of Osteoarthritis of the Knee, Hip, and Hand. American College of Rheumatology (approved summary; full manuscript pending), 2026.Approved September 8, 2026: strong recommendations for exercise, weight loss (knee/hip OA with overweight), topical NSAIDs (knee/hand) and oral NSAIDs; tai chi is now conditional. It strongly recommends against glucosamine, chondroitin and combination products, and conditionally against intra-articular hyaluronic acid, fish oil and vitamin D; Boswellia, ASU and curcumin are not addressed.
9. Health Products Compliance Guidance. Federal Trade Commission, 2022.Health claims need competent and reliable scientific evidence, generally randomized controlled human trials; animal and lab studies are not enough on their own. Marketers relying on ingredient studies must confirm dose and formulation are comparable, and testimonials do not substitute for scientific evidence.
10. Federal Trade Commission Announces Final Rule Banning Fake Reviews and Testimonials. Federal Trade Commission press release, 2024.Announced August 14, 2024, the rule bans fake reviews and testimonials (including AI-generated ones and those by people with no real experience), buying reviews conditioned on positive or negative sentiment, undisclosed insider reviews, and company-controlled review sites posing as independent. It lets the FTC seek civil penalties against knowing violators.